SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2021 / Cilt: 3 - Sayı: Supplement 1

A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Murat ÇALAPKULU
Muhammed Erkam SENCAR
İlknur ÖZTÜRK ÜNSAL
Hayri BOSTAN
Erman ÇAKAL
Pages
85–86
Publication Date
2021-03-07
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients.
📊
Key Findings & Data:Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
💡
Conclusion & Impact:In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Dapagliflozin · sodium-glucose co-transporter 2 inhibitors · euglycemic ketoacidosis

Abstract

Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.

🔖

Cite This Article

ÇALAPKULU, M., SENCAR, M. E., ÜNSAL, İ. Ö., BOSTAN, H., ÇAKAL, E. (2021). A case report of euglycemic ketoacidosis due to dapagliflozin treatment. Turkish Journal of Internal Medicine, Cilt: 3 - Sayı: Supplement 1, 85–86. https://ajindex.com/articles/809086

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9(7):551–9
  2. Dhatariya KK, Umpierrez GE. Guidelines for management of diabetic ketoacidosis: time to revise? Lancet Diabetes Endocrinol 2017;5(5):321–3
  3. Yu X, Zhang S, Zhang L. Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. Int J Endocrinol 2018;2018:7074868
  4. Fralick M, Schneeweiss S, Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med 2017;376(23):2300–2
  5. Food and Drug Administration, FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the bloodNovember 2019
  6. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015;100(8):2849–52
  7. American Diabetes Association
  8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(Suppl 1):S111–24
  9. Burke KR, Schumacher CA, Harpe SE. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature. Pharmacotherapy 2017;37(2):187–94.